Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? by Derks, J.L. (Jules L.) et al.
Is the sum of positive neuroendocrine immunohistochemical
stains useful for diagnosis of large cell neuroendocrine
carcinoma (LCNEC) on biopsy specimens?
Jules L Derks,1 Anne-Marie C Dingemans,1 Robert-Jan van Suylen,2
Michael A den Bakker,3,4 Ronald A M Damhuis,5 Esther C van den Broek,6
Ernst-Jan Speel7 & Erik Thunnissen8
1Department of Pulmonary Diseases, GROW school for Oncology and Developmental Biology, Maastricht University
Medical Centre, Maastricht, 2Pathology-DNA, Jeroen Bosch Hospitals’, Hertogenbosch, 3Department of Pathology,
Maasstad Hospital, Rotterdam, 4Department of Pathology, Erasmus MC, Rotterdam, 5Department of Research,
Comprehensive Cancer Association, Utrecht, 6PALGA Foundation, Houten, 7Department of Pathology, GROW School
for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, and 8Department of
Pathology, VU University Medical Centre, Amsterdam, the Netherlands
Date of submission 30 August 2018
Accepted for publication 25 November 2018
Published online Article Accepted 28 November 2018
Derks J L, Dingemans A-M C, van Suylen R-J, den Bakker M A, Damhuis R A M, van den Broek E C, Speel E-J,
Thunnissen E
(2019) Histopathology 74, 555–566. https://doi.org/10.1111/his.13800
Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of
large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?
Aims: Pulmonary large cell neuroendocrine carci-
noma (LCNEC) is underdiagnosed on biopsy speci-
mens. We evaluated if routine neuroendocrine
immunohistochemical (IHC) stains are helpful in the
diagnosis of LCNEC on biopsy specimens.
Methods and results: Using the Dutch pathology reg-
istry (PALGA), surgically resected LCNEC with match-
ing pre-operative biopsy specimens were identified and
haematoxylin and IHC slides (CD56, chromogranin-A,
synaptophysin) requested. Subsequently, three pathol-
ogists assigned (1) the presence or absence of the WHO
2015 criteria and (2) cumulative size of all (biopsy)
specimens. For validation, a tissue microarray (TMA)
of non-small-cell lung cancer (NSCLC) (n = 77) and
LCNEC (n = 19) was used. LCNEC was confirmed on
the resection specimens in 32 of 48 re-reviewed cases.
In 47% (n = 15 of 32) LCNEC was also confirmed in
the paired biopsy specimens. Neuroendocrine morphol-
ogy was absent in 53% (n = 17 of 32) of paired biopsy
specimens, more often when smaller amounts of tissue
were available for evaluation [29% < 5 mm (n = 14)
versus 67% ≥5 mm (n = 18) P = 0.04]. Combined
with current WHO criteria, positive staining for greater
than or equal to two of three neuroendocrine IHC
markers increased the sensitivity for LCNEC from 47%
to 93% on paired biopsy specimens, and further vali-
dated using an independent TMA of LCNEC and NSCLC
with sensitivity and specificity of 80% and 99%,
respectively.
Conclusions: LCNEC is difficult to diagnose because
neuroendocrine morphology is frequently absent in
biopsy specimens. In NSCLC devoid of obvious mor-
phological squamous or adenocarcinoma features,
positive staining in greater than or equal to two of
three neuroendocrine IHC stains supports the diagno-
sis of LCNEC.
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Introduction
In lung cancer most diagnoses are made on relatively
small biopsies and cytology.1 The histological features
pointing to diagnosis adenocarcinoma, squamous-cell
carcinoma or LCNEC may be challenging.2 The dis-
tinction between adenocarcinoma and squamous-cell
carcinoma in the context of non-small-cell lung carci-
noma not otherwise specified (NSCLC-NOS) has been
addressed in the World Health Organisation (WHO)
classification of lung tumours of 2015 by the intro-
duction of several markers, including mucin, thyroid
transcription factor-1 (TTF1) and P63/P40.3 More
recently, the added value of immunohistochemical
(IHC) markers in the differential diagnosis of small-
cell lung carcinoma (SCLC) has been described.4
LCNEC is a high-grade neuroendocrine carcinoma
originally described in 1991.5 The diagnostic criteria
for LCNEC include observation of abundant mitoses
(>10 mitosis/2 mm2), neuroendocrine morphology
such as rosettes, trabecular growth pattern or pal-
isading of cells and neuroendocrine differentiation
usually identified by IHC markers. Although in recent
practice LCNEC has been diagnosed more frequently
on biopsy specimens,6 the diagnostic accuracy and
precision for a diagnosis of LCNEC on a biopsy speci-
men is unknown and not well studied.7–11
As described by national guidelines, one of the
first-line treatment options for non-squamous NSCLC
is cisplatinum-pemetrexed chemotherapy.12 A patient
with metastatic LCNEC disease that is not recognised
as such, because neuroendocrine morphology is lack-
ing in a biopsy specimen, may be diagnosed as non-
squamous NSCLC (i.e. P63-negative, TTF1-positive or
-negative) and treated with cisplatinum-pemetrexed
chemotherapy. Recently, a study evaluating outcome
of 128 patients with metastatic LCNEC reported an
inferior outcome for cisplatinum-pemetrexed and plat-
inum-etoposide chemotherapy compared to platinum-
gemcitabine/paclitaxel chemotherapy.13 Therefore, it
is clinically relevant to reliably separate LCNEC from
NSCLC on biopsy specimens.
The purpose of this study was to establish if the
outcome of the current frequently used neuroen-
docrine IHC stains on biopsy samples may be helpful
in the diagnosis of LCNEC. To this end, two indepen-
dent cohorts of LCNEC and a cohort of NSCLC were
examined for the presence of diagnostic criteria for
LCNEC by a panel of pathologists as well as the out-
come of three IHC stains (CD56, chromogranin A,
synaptophysin).
Material and methods
R E G U L A T I O N S
The study protocol was approved by the medical ethical
committee of the Maastricht University Medical Centre
(METC azM/UM 14-4-043) and was performed accord-
ing to the Dutch Federa, Human Tissue and Medical
Research: Code of Conduct for Responsible Use (2011)
regulations not requiring patient informed consent.
P A T I E N T A N D T U M O U R S E L E C T I O N
In this retrospective population-based study all data
were retrieved from the Netherlands Cancer Registry
and Netherlands Pathology Registry (PALGA, the
nationwide registry of pathology in the Netherlands14),
as described previously. In short, by screening digital
summaries of pathology reports, 994 patients with
LCNEC were identified in the combined data sets of
patients diagnosed between 1 January 2003 and 31
December 2012. In a total of 326 (33%) LCNEC
patients the primary tumour was surgically removed.
By screening the patient pathology history, we identi-
fied 110 (34%) patients in whom a histopathological
biopsy specimen was obtained from the matching
anatomical location where the tumour was surgically
removed (i.e. a paired pre-operative biopsy-resection
specimen). From 60 of the 110 cases, haematoxylin
and eosin (H&E) and IHC stains of both the resection
and biopsy specimens were available for panel revision
(Figure 1). Subsequently, 12 cases were excluded
because the original H&E tumour slide(s) were deemed
inadequate by reviewing pathologists.
P A N E L C O N S E N S U S P A T H O L O G Y R E V I S I O N
The retrieved IHC stains included the neuroendocrine
markers [chromogranin-A, synaptophysin and CD56
(NCAM)], TTF1, P63, Ki-67 and available cytokeratin
markers. All IHC markers were stained in routine
diagnosis. All cases minimally required an H&E stain
and one of three neuroendocrine IHC markers, as
described previously. Subsequently, all tumour slides
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 555–566.
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were systematically evaluated by three pathologists
(R.v.S., M.d.B. and E.T.) using a multihead micro-
scope. All pathologists were blinded for clinical out-
come and for matching biopsy-resection specimens.
Total tissue size of the biopsy specimens was esti-
mated by applying the following categories: ≤2, >2
but ≤5, >5 but ≤10 and >10 mm. The total size of
the samples was evaluated guided by the field of view
of the microscope objective. In overview magnifica-
tion (92.5) the total size should well exceed the field
of view (diameter 8 mm) to be larger than 10 mm; if
at 92.5 objective the total size was smaller than the
maximum, but covering more than half the field of
view, the size was between 5 and 10 mm; smaller
samples were evaluated at 910 objective: if the total
sample size was smaller than the field of view (diame-
ter 2 mm) then the total size was less than 2 mm, or
it was between 2 and 5 mm.
H&E slides of both resection and biopsy specimens
were examined for (i) cell type, presence of cytoplasm
and tumour to lymphocyte ratio to assess NSCLC of
SCLC features according to the WHO 2015 classifica-
tion, (ii) the presence of neuroendocrine morphology,
(iii) estimated mitotic activity in non-crushed fields
[≤10, 11–30 or >30 mitoses/10 high-power field
(HPF)], (iv) necrosis [none, ‘dot-like’ (=as occasionally
seen in atypical carcinoids) or abundant (= more
extensive than ‘dot-like’)]. If available, the MIB1 (Ki-
67) staining was scored into <25% and >25%.15,16
In more limited tissue samples (<2 mm2), mitoses
Netherlands Cancer Registry
LCNEC
Neuroendocrine carcinoma
NSCLC NED
(01.01.2003-31.12.2012)
N = 1116
N = 380
N = 131
Netherlands Pathology Registry
LCNEC N = 1172
(01.01.2003-31.12.2012)
Application of clinical selection criteria 
& manual screening of summaries 
of pathology reports 
N = 2066 unique patients
excluded
No pre-operative pathology specimen
Paired biopsy-resection specimens
available for panel-consensus revision
N = 48
Surgically resected LCNEC specimens
N = 326
Paired biopsy-resection specimen
N = 110
N = 176
Cytology specimen N = 40
Original slides unavailable N = 50
excluded
excluded
N = 1 740No surgical specimen or not LCNEC 
Resection specimen LCNEC
N = 32
other resection specimen panel diagnoses
N = 1
N = 9
N = 1
N = 3
N = 2
Atypical carcinoid
SCLC
NSCLC NED
Inconclusive, dd LCNEC
Other (possible sarcoma)
Original slides inadequate for revision N = 12
Pre-operative LCNEC biopsy specimen
with >1 neuroendocrine IHC marker 
available (CD56/Syn or Chr-A)
N = 26
Figure 1. Selection of surgical LCNEC specimens with pre-operative biopsy specimens available for panel review. N, number; LCNEC, large
cell neuroendocrine carcinoma; NSCLC NED, non-small-cell lung carcinoma with immunohistochemical neuroendocrine differentiation;
SCLC, small-cell lung carcinoma; IHC, immunohistochemistry; Syn, synaptophysin; Chr-A, chromogranin-A.
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were evaluated on all assessable HPFs.4 Either
>10 mitoses/2 mm2, abundant tumour necrosis or a
Ki-67 staining of more than 25% of tumour cells was
sufficient to score for high-grade tumour disease.15
Chromogranin-A and synaptophysin were scored as
(+) on observation of focal small cytoplasmic dots in
an occasional tumour cell at 940 microscope. Any
membrane staining was sufficient for CD56 (+). For
all neuroendocrine markers, observation of staining
(94 or 92.5 objective) was scored as strongly posi-
tive (+++), and between staining as (++). Addition-
ally, p63/p40/TTF1 and cytokeratin stainings were
evaluated when these were available. LCNEC diag-
noses were established when both neuroendocrine
morphology and neuroendocrine staining of at least a
single marker was present, as according to the algo-
rithm as described in the WHO classification (2015).
T I S S U E M I C R O A R R A Y F O R V A L I D A T I O N
A TMA cohort was constructed from adenocarcinoma
(n = 33), squamous cell carcinoma (n = 29) NSCLC
not otherwise specified (n = 15), carcinoid (n = 18),
LCNEC (n = 19) and SCLC (n = 3) surgically resected
tumours diagnosed at Maastricht University Medical
Centre (1998–2015). Three cores, each 2-mm thick,
were sampled into a donor block. Staining for
chromogranin-A (DAK-A3), synaptophysin (DAK-
SYNAP), CD56 (123C3), TTF1 (SPT24), P63 (DAK-
P63) and KI67 (DAK-7240) was performed according
to routine diagnostic protocols. Expression of IHC
markers were evaluated by J.D. and E.T. and scored
using H-score; P-63 was scored positive when H-score
>200. TMA cores were evaluated for diagnosis by a
single pathologist (E.T.), who was blinded for the origi-
nal diagnosis according to (1) the WHO 2015 criteria
and (2) the WHO 2015 with addition of newly pro-
posed LCNEC criteria for limited tissue samples.
S T A T I S T I C S
All analyses were performed using SPSS (version 22
for Windows, Inc., Chicago, IL, USA). To compare
categorical data, the v2 and Fisher’s exact test were
used. Two-sided P-values of <0.05 were considered
significant.
Results
P A I R E D R E S E C T I O N - B I O P S Y S P E C I M E N
C O M P A R I S O N
In total, 48 cases of LCNEC were available for panel
review. After reviewing all resection specimens, only
LCNEC
47%
NEC 6%Carcinoid 3%
NSCLC
44%
A Biopsy diagnoses of paired resection
specimen with a lcnec diagnosis (N = 32)
LCNEC
83%
SCLC 11%
Other 6%
B Resection diagnoses of paired biopsy
specimen with a lcnec diagnosis (N = 18)
Figure 2. A, Overview of diagnoses established on paired pre-operative biopsy specimens of surgically diagnosed LCNEC by panel-consensus
revision (n = 32); samples were taken from identical anatomical regions. B, Overview of diagnoses established on the resection specimens of
paired pre-operative biopsy specimens diagnosed as LCNEC (n = 18). Others included here are cases without a unanimous diagnosis by the
classifying pathologists. LCNEC, large cell neuroendocrine carcinoma; SCLC, small-cell lung carcinoma; NSCLC, non-small-cell lung cancer;
NEC, neuroendocrine carcinoma not otherwise specified.
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 555–566.
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32 of 48 cases were revised as LCNEC (Figure 1). In
only 47% (15 of 32) of these revised LCNEC cases
was the diagnosis of LCNEC also established on the
paired biopsy specimens. Other paired biopsy speci-
men diagnoses (17 of 32) included NSCLC (44%),
carcinoid (3%) and inconclusive diagnosis (6%),
respectively (Figure 2A). In total, 18 of 48 pre-opera-
tive biopsy specimens were revised as LCNEC; paired
revised resection diagnosis was LCNEC in 83%; other
diagnoses included SCLC (12%) and a non-unani-
mous revised case (overview Figure 2B). An overview
of all diagnostic criteria identified in the paired biopsy
specimens of revised confirmed surgically resected
LCNEC is presented in Table 1 and an exemplar case
in Figure 3A,B.
Data of non-LCNEC revised resected cases are pre-
sented in Supporting information, Table S1, and
mainly included SCLC (n = 9). Paired biopsy specimen
diagnoses of these SCLC cases included LCNEC
(n = 2), SCLC (n = 1) and NSCLC (n = 5), and one
had a differential diagnosis of SCLC versus NSCLC,
respectively.
E V A L U A T I O N O F W H O C R I T E R I A O N T H E P A I R E D
B I O P S Y S P E C I M E N S
When evaluating the paired biopsy specimens from
surgically confirmed LCNEC, the WHO 2015 criteria
could only be observed to a variable extent. Overall,
‘neuroendocrine morphology’ was not observed in
50% of biopsy samples. However, in biopsy samples
with a cumulative size of >5 mm tumour tissue this
morphology was more frequently observed compared
to smaller samples [67% versus 29%, respectively
(P = 0.04), Table 2]; an exemplar biopsy case is
shown in Figure 3C. Comparison of the cumulative
biopsy size revealed no significant difference for the
presence of mitosis, nucleoli, cytoplasm and necrosis.
E V A L U A T I O N O F N E W D I A G N O S T I C C R I T E R I A F O R
L C N E C O N B I O P S Y S P E C I M E N S
We then hypothesised that in LCNEC biopsy speci-
mens lacking neuroendocrine morphology, the neu-
roendocrine marker staining pattern may be of
additional diagnostic value. For 26 of 32 confirmed
LCNEC cases, two or more neuroendocrine markers
were available (Figure 1). When the presence of
staining for ≥2 neuroendocrine IHC markers was con-
sidered as a surrogate marker for neuroendocrine
morphology in the biopsy specimens, then the diag-
nosis of LCNEC would have increased from 47%
(n = 15 of 32) to 81% (n = 26 of 32). When cases
were excluded in which fewer than two neuroen-
docrine markers were available and lacked neuroen-
docrine morphology (n = 4), the recognition of
LCNEC would increase to 93% (n = 26 of 28). An
exemplar case can be found in Figure 3C,D.
V A L I D A T I O N U S I N G A N I N D E P E N D E N T T M A
T U M O U R C O H O R T
To validate the hypothesis that ≥2 neuroendocrine
IHC markers staining in the diagnostic setting of
NSCLC supports the diagnosis of LCNEC, a TMA of an
independent tumour cohort was used. Expression of
≥2 neuroendocrine markers in LCNEC was observed
in 15 of 19 (79%) and in 18 of 18 (100%) carcinoid
and three of three (100%) SCLC tumours, respec-
tively. Staining for ≥2 neuroendocrine markers
occurred in only one of 77 (1%) NSCLC cases with
strong staining for CD56 and faint staining for synap-
tophysin. Expression of a single neuroendocrine mar-
ker was observed in 11 of 77 (14%) of NSCLC,
mostly CD56 (n = 4) or synaptophysin (n = 7). A
summary of identified IHC expression patterns can be
found in Table 3, specified in the Supporting informa-
tion, Table S2 and the Supporting information
Data S1. Using the current 2015 WHO criteria, only
nine of 19 (47%) LCNEC were identified correctly on
the TMA cohort (ET).
Discussion
Our retrospective study shows that in biopsy speci-
mens positivity for ≥2 of three neuroendocrine mark-
ers may support the diagnosis of LCNEC in cases
devoid of neuroendocrine morphology in undifferenti-
ated or TTF1-positive NSCLC. Adding this IHC crite-
rion to the current WHO classification will increase
the sensitivity of the diagnosis of LCNEC on biopsy
specimens from 47% to 79–93%, providing an oppor-
tunity for better treatment in patients with LCNEC.
As LCNEC is not diagnosed on biopsy specimens,
these cases will currently be called adenocarcinoma
when TTF1 is positive, or NSCLC not otherwise speci-
fied. Our study provided an argument that in smaller
biopsies the chance of identifying neuroendocrine
morphology is lower than in larger biopsies, explain-
ing the difficulty of diagnosing LCNEC on morphology
criteria alone.
In NSCLC neuroendocrine immunohistochemical
staining with chromogranin-A, synaptophysin and
CD56 was mainly performed on resection speci-
mens.17–22 Focal IHC staining for one neuroendocrine
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 555–566.
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marker is not infrequent, and has no prognostic or
therapeutic relevance. According to the current WHO
classification, IHC for neuroendocrine differentiation
should therefore not be applied for diagnostic purposes
when neuroendocrine morphology is absent.3,23 The
reported range of one of the three neuroendocrine
markers in squamous cell carcinomas, and adenocarci-
nomas are more or less similar (8–31% and 17–33%,
respectively, see Table 3).17–22,24 Interestingly, positiv-
ity for two of the three common neuroendocrine mark-
ers in NSCLC is present in only 1–3.8%.18,24,25 This
suggests that if applied as an additional diagnostic cri-
terion for LCNEC, the specificity of this criterion may
be >96%. Positive staining of ≥2 of the three common
neuroendocrine markers is reported in ≥80% of
LCNEC,26,27 which is completely in line with the two
cohorts evaluated in our study. These data suggest
that the sensitivity of this criterion for the diagnosis of
LCNEC will be approximately 80%. The high sensitivity
and specificity may, if applied in the diagnostic process
10x
KI -67
40xA
B
C
D
Chr ACD56 TTF1
10x
40x CD56 Chr A
Ki-67
TTF1
10x
40x CD56 Chr ASyn
P63 Ki-67TTF1
P63 Ki-67TTF1
10x
40x CD56 Chr ASyn
Figure 3. A–D, Overview of haematoxylin and eosin (H&E) and
immunohistochemistry (IHC) staining in paired pre-operative
biopsy-resection specimens’ consensus diagnosed as LCNEC on the
resection specimens. LCNEC, large cell neuroendocrine carcinoma;
NSCLC, non-small-cell lung carcinoma. Biopsy specimen (A)
(matched with resection specimen B): according to the established
WHO classification, NSCLCs favouring LCNEC would be diagnosed.
Neuroendocrine morphology (palisading, arrow) is observed. The
left upper panel shows cells with non-small-cell cytological features.
CD56 and chromogranin-A staining confirm neuroendocrine differ-
entiation (upper middle panels), thyroid transcription factor-1
(TTF1) is positive (upper right), while high-grade disease is con-
firmed with the Ki-67 staining (>25%, lower right panel). Resection
specimen (B) (matched with biopsy specimen A): according to the
established WHO classification, LCNEC would be diagnosed. Identi-
cal to the biopsy specimen, neuroendocrine morphology is present
(palisading, white arrow). In the left upper panel non-small-cell
cytological features can be observed with abundant cytoplasm and
nucleoli (arrow). The black arrow highlights a mitosis, while the
Ki-67 (lower right panel) confirms high-grade disease (>25%).
Biopsy specimens (C) (matched with resection specimen D): accord-
ing to the established WHO classification, NSCLCs favouring adeno-
carcinoma would be diagnosed. According to the current study, the
proposed diagnosis will be LCNEC, confirmed in the resection speci-
men (D). In the overview, an undifferentiated NSCLC is observed
(cytological features, left upper panel). P63 is negative but TTF1 is
strongly positive (middle lower panel). High-grade disease is con-
firmed with the Ki-67 (>25%, lower right panel). The neuroen-
docrine marker CD56 shows modest membranous staining (upper
middle left), synaptophysin shows granular staining (upper middle
right) while chromogranin-A is negative (upper right). Resection
specimen (D) (matched with biopsy specimen C): according to the
established WHO classification, LCNEC would be diagnosed. In the
overview, a neuroendocrine morphology is present (white arrows)
and cytological features of a non-small cell with abundant cyto-
plasm (left upper panel). Immunohistochemical markers show iden-
tical patterns to the biopsy specimen (middle lower and upper
panels).
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of LCNEC, lead to an increase in the diagnostic accu-
racy of LCNEC on biopsy specimens requiring confir-
mation in further studies.
For the interpretation of neuroendocrine differentia-
tion, care must be taken not to make a false positive
call. This may occur in a tumour-circumvented bron-
chiole with occasional neuroendocrine cells or by
CD56 positivity on intratumoral lymphocytes. More-
over, for judging chromogranin-A, evaluation of
tumour cells at a 940 objective is essential to detect
Table 2. Comparison of WHO criteria evaluated in the
paired pre-operative biopsy and resection specimens of
LCNEC
WHO 2015
criteria
Specimen type
P-
value*
Pre-operative biopsy
Resection
<5 mm
versus
>5 mmTotal <5 mm ≥5 mm Total
Total (n) 32 14 18 32 –
Mitosis (% scored
as in resection
specimen)
72% 57% 83% – 0.13
≤10 4 2 2 0
>10 23 8 15 31
Not assessable 5 4 1 1
Necrosis (%
scored as in
resection
specimen)
63% 50% 72% – 0.28
Large zones 20 5 15 26
Dotlike (focal
necrosis as in
AC)
1 0 1 4
No necrosis 10 9 1 2
Not assessable 1 0 1 0
Neuroendocrine
morphology (%
scored as in
resection
specimen)
50% 29% 67% – 0.04**
Not present 9 4 5 0
Present 15 5 10 31
Heterogeneous
among
pathologists
3 0 3 1
Not assessable 5 5 0 0
≥2/10 large (non-
inconspicuous)
nucleoli (%
scored as in
resection
specimen)
59% 50% 67% – 0.47
No 28 11 17 18
Yes 3 3 0 13
Heterogeneous
among
pathologists
0 0 0 1
Table 2. (Continued)
WHO 2015
criteria
Specimen type
P-
value*
Pre-operative biopsy
Resection
<5 mm
versus
>5 mmTotal <5 mm ≥5 mm Total
Not assessable 1 0 1 0
Cytoplasm as in
NSCLC (%
scored as in
resection
specimen)
88% 93% 83% – 0.61
No 1 1 0 1
Yes 29 13 16 30
Heterogeneous
among
pathologists
1 0 1 1
Changing
within
specimen (i.e.
yes and no)
0 0 0 0
Not assessable 1 0 1 0
Moulding (%
scored as in
resection
specimen)
69% 86% 55% – 0.12
No 25 13 12 25
Yes 3 0 3 0
Heterogeneous
among
pathologists
2 0 2 6
Not assessable 2 1 1 1
NSCLC, non-small cell lung carcinoma, AC, atypical carcinoid; mm,
millimeters.
*Fisher’s exact test comparing number of paired and resection
specimens identically scored for WHO criteria subcategory.
**v2 test comparing number of paired and resection specimens
identically scored for WHO criteria subcategory (i.e. neuroen-
docrine morphology present in both specimens).
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occasional dot-like positivity of small cytoplasmic
granules, which may not be observed with the 92.5–
10 microscope objective.
Previous studies that aimed to evaluate the LCNEC
WHO 2015 criteria on biopsy specimens have shown
high diagnostic specificity.7–11 Similarly, we provide
evidence that the specificity for LCNEC on a biopsy
specimen is acceptable (i.e. 83%). Nonetheless, we
observed that several biopsy specimens diagnosed as
LCNEC were classified as SCLC in the resection speci-
mens. This is probably explained by tumour hetero-
geneity and the difficulty in assessing cytological
features in biopsy specimens, as addressed previ-
ously.4,28 This imperfect specificity may affect the
results of chemotherapy studies, as was suggested
recently.29
Several recently described markers may aid in the
differential diagnosis of LCNEC on biopsy specimens
and require further evaluation. The insulinoma-asso-
ciated protein 1 (INSM1) is a transcription factor of
neuroendocrine differentiation proposed as a pan-neu-
roendocrine marker that outperforms traditionally
used markers, with similar specificity as chromo-
granin A and comparable sensitivity to CD56 and
Table 3. Overview of neuroendocrine IHC marker staining in adenocarcinomas and squamous cell carcinomas and reported
clinical relevance
Authors TMA Morphology Any (+) CD56 Chr-A Synaptophysin >2 markers
Gonzalez
Argoneses
et al.
Yes
(>10% of cells)
AdC n = 156
SqCC n = 128
– – – 52 (33%)
34 (21%)
–
Pelosi
et al.
No
(median of 2000
cells)
AdC n = 88
SqCC n = 113
15 (17%)
13 (12%)
– 0 (0%)
2 (2%)
3 (4%)
7 (6%)
–
Segawa
et al.
No
(focal or more)
AdC n = 55
SqCC n = 50
15 (27%
4 (8%)
7 (18%)
2 (4%)
4 (7%)
1 (2%)
8 (15%)
0 (0%)
–
Sterlacci
et al.
Yes
(any positivity)
AdC n = 197
SqCC n = 119
38 (19%)
7 (6%)
10 (5%)
3 (3%)
2 (1%)
0 (0%)
28 (16%)
4 (3%)
–
Hage
et al.
No
(UA)
AdC n = 262
SqCC n = 575
– 30 (11%)
86 (15%)
– – –
Ionescu
et al.
Yes
(>1% cell positivity)
AdC n = 243**
SqCC
n = 272**
76 (31%)
83 (31%)
11 (5%)
29 (12%)
1 (1%)
1 (1%)
23 (11%)
10 (4%)
3 (1%)
2 (1%)
Howe
et al.
Yes
(>focal weak)
NSCLC*
n = 341
157 (36%) 44 (28%) 9 (6%) 27 (17%) –
Rooper et al. Yes
(any positivity)
AdC n = 61
SqCC n = 95
8 (13%)
7 (7%)
3 (5%)
7 (7%)
1 (2%)
0 (0%)
4 (7%)
1 (1%)
–
Ye et al. Yes
(>5% cell positivity)
AdC n = 183
SqCC n = 101
28 (15%)
12 (12%)
3 (2%)
8 (8%)
10 (6%)
6 (6%)
22 (12%)
2 (2%)
7 (4%)
3 (3%)
Derks et al. Yes
(any positivity)
AdC n = 33
SqCC n = 29
NSCLC
NOS = 15
6 (18%)
1 (3%)
4 (27%)
3 (10%)
1 (3%)
1 (7%)
0 (0%)
0 (0%)
0 (0%)
4 (12%)
1 (3%)
2 (13%)
0 (0%)
0 (0%)
1 (7%)
Total AdC
SqCC
NSCLC
186/860
(22%)
126/808
(15%)
473/2024
(23%)
67/1034
(6%)
136/1241
(11%)
248/2631
(9%)
18/860
(2%)
10/808
(1%)
37/2009
(2%)
140/1016
(14%)
59/907
(7%)
226/2264
(10%)
10/459
(2%)
5/402
(1%)
15/861
(2%)
AdC, adenocarcinoma; SqCC, squamous cell carcinoma; Syn, synaptophysin, Chr-A, chromogranin-A; UA; unavailable; TMA, tissue microar-
ray.
*Combination of morphological differentiated AdC, SqCC, large cell carcinoma and adenosquamous carcinomas.
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synaptophysin.30,31 INSM1 stains 75–91% of LCNEC
and focal staining is observed in 0–4% of NSCLC.30–
32 The value of INSM1 in an algorithm of ≥2 neu-
roendocrine markers staining for biopsies to recognise
LCNEC is unclear. Furthermore, recent studies have
addressed the existence of different molecular sub-
types of LCNEC.27,33,34 Proposed are the LCNEC-SCLC
with TP53/RB1 mutations recognised with IHC by
loss of the RB1 protein and the LCNEC-NSCLC sub-
type with STK11/KEAP/KRAS mutations and the
presence of RB1 protein staining.27,35 In the differen-
tial diagnosis of LCNEC versus SCLC, staining of RB1
IHC is indicative of a non-SCLC-like tumour.4 Finally,
napsin-A is proposed as a marker to differentiate the
TTF1-positive molecular LCNEC-NSCLC subtype from
adenocarcinoma, as only few show focal staining for
napsin-A while all adenocarcinomas show (strong)
staining for both markers.36
Our study was restricted by the limited number of
paired biopsy-resection specimens evaluated by the
panel of pathologists. Nevertheless, the described diag-
nostic issues in this study reflect the daily clinical prac-
tice closely. Furthermore, this is the first substantial
analysis of the established WHO criteria for LCNEC on
biopsy specimens using matched resection specimens.
In conclusion, positivity for two of three tradition-
ally used neuroendocrine IHC stains leads to a useful
increase in the diagnostic accuracy of LCNEC on
biopsy specimens.
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